Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen reports clinical data showing survival benefits of Kyprolis

Amgen reports clinical data showing survival benefits of Kyprolis

7th June 2016

Amgen's multiple myeloma drug Kyprolis has demonstrated its survival benefits in a new phase III clinical trial.

A secondary analysis of the ASPIRE trial showed Kyprolis, when used in combination with lenalidomide and dexamethasone, improved progression-free survival and overall response rates compared to lenalidomide and dexamethasone alone in patients with relapsed multiple myeloma with early disease progression after initial therapy or transplant.

Patients relapsing within one year of initial therapy treated with the Kyprolis-based regimen experienced a median progression-free survival rate of 24.1 months, compared to 12.5 months in those treated without Kyprolis.

Overall response rates were also better when using Kyprolis.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "The addition of Kyprolis to lenalidomide and dexamethasone resulted in patients living longer without their disease progressing, a significant milestone for patients living with this difficult-to-treat disease."

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the drug for approval in the treatment of relapsed multiple myeloma last week.ADNFCR-8000103-ID-801819821-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.